Company intelligence / Profile preview

Amnis Therapeutics

Or Akiva, Sharon Area, Israelprnewswire.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Preclinical studies demonstrated safety and efficacy for the Golden Retriever neurothrombectomy device. The first clinical trial was initiated in early 2017. The device offers advantages such as small size, flexibility, and effective clot retrieval compared to competitors. No published results from later-stage trials are available.

Therapeutic areas: CardiovascularNeurology
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Golden Retriever

Phase 1

Indications: Acute Ischemic Stroke

Beyond the preview

Go deeper on Amnis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amnis Therapeutics.

Explore the full profile